Cell News and Research

RSS

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.

25 Aug 2009

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

University of Manchester researchers found that a special type of the chemicals known as 'kinase inhibitors' opened up communication channels on the surface of cells that enabled healthy cells to 'talk' to the cancer cells.

From The University of Manchester 25 Aug 2009

Biotime completes the process of issuing common shares and warrants under its revolving line of credit agreement

BioTime, Inc. (OTCBB: BTIM) announced today that it has completed an Exchange Offer to the holders of notes issued under its revolving line of credit agreement. BioTime issued 1,989,515 common shares and warrants to purchase 100,482 common shares in exchange for notes in the aggregate principal amount of $3,349,259.

25 Aug 2009

Cord Blood America announces retirement of $1.6 million in debt since July 2009

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.

25 Aug 2009

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

In order to reduce the Province's greenhouse gas emissions, the BC Bioenergy Strategy is calling for greatly increased production of renewable biofuels such as ethanol, from biomass grown in BC. Two new research projects, largely funded by Genome BC, will help to answer these questions and unlock the valuable green energy found within BC's forests.

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

The NanoBusiness Alliance, the world's leading nanotechnology trade association, today announced details of its expanded conference program for the 8th annual NanoBusiness 2009 conference and exhibition, which will held at McCormick Place in Chicago, IL, from September 8 – 10.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

OriGene Technologies releases recombinant proteins purified from HEK293 cells

OriGene Technologies, Inc. announces the release of 5,000 purified human proteins, representing the most comprehensive offering of human cell-produced human proteins.

25 Aug 2009

Combined therapy for acute leukemia shows promising results

Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

25 Aug 2009

University of Southampton develops a microfluidic single-cell impedance cytometer for blood cell analysis

A hand-held device which could offer point-of-care blood cell analysis in doctors' surgeries is being developed by academics at the University of Southampton and is described in a paper in Lab on a Chip this month.

25 Aug 2009

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, is accepting grant applications for a new initiative to establish a consortium of human immune profiling research centers.

25 Aug 2009

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

REGENERX BIOPHARMACEUTICALS, INC. (the “Company” or “RegeneRx”) announced today that it received a “Notice of Allowance” in Europe for its patent application: Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides.

25 Aug 2009

PLoS journal throws light on neglected tropical diseases toll in sub-Saharan Africa

An analysis published August 25 in the open-access journal PLoS Neglected Tropical Diseases sheds new light on the toll that neglected tropical diseases (NTDs) take on sub-Saharan Africa (SSA), with an estimated 500 million people suffering from these debilitating and sometimes deadly diseases.

25 Aug 2009

PacifiCord to conduct free prenatal classes in San Diego from September 2009

Dedicated to serving the private cord blood banking needs of Southern California, PacifiCord (www.pacificord.com) today announced it will be offering free prenatal classes in San Diego starting September 9, 2009.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Even as low-carbohydrate/high-protein diets have proven successful at helping individuals rapidly lose weight, little is known about the diets' long-term effects on vascular health.

25 Aug 2009

Scientists cultivate multiple types of retina cells from human stem cells

A team of scientists from the University of Wisconsin-Madison School of Medicine and Public Health has successfully grown multiple types of retina cells from two types of stem cells — suggesting a future in which damaged retinas could be repaired by cells grown from the patient's own skin.

25 Aug 2009

USDA donates funds for teaching food safety awareness to AIDS patients

Researchers at the University of Illinois at Chicago School of Public Health have received a grant from the U.S. Department of Agriculture to educate AIDS patients on food safety.

25 Aug 2009

Cell News and Research

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

Biotime completes the process of issuing common shares and warrants under its revolving line of credit agreement

Cord Blood America announces retirement of $1.6 million in debt since July 2009

Genome BC's research projects to determine efficient methods of liberating fermentable sugars from dead pine

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

OriGene Technologies releases recombinant proteins purified from HEK293 cells

Combined therapy for acute leukemia shows promising results

University of Southampton develops a microfluidic single-cell impedance cytometer for blood cell analysis

NIAID to establish a human immune profiling research consortium in 2010; invites grant applications

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

PLoS journal throws light on neglected tropical diseases toll in sub-Saharan Africa

PacifiCord to conduct free prenatal classes in San Diego from September 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Low-carbohydrate and high-protein diet increases the risk for atherosclerosis and impaired blood vessels

Scientists cultivate multiple types of retina cells from human stem cells

USDA donates funds for teaching food safety awareness to AIDS patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News